about
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stabilityMultiple Wnt/ß-catenin responsive enhancers align with the MYC promoter through long-range chromatin loopsIκB kinases increase Myc protein stability and enhance progression of breast cancer cellsDLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYCRetroviral oncogenes: a historical primerNoninvasive molecular imaging of c-Myc activation in living miceRegression of murine lung tumors by the let-7 microRNAEmerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer developmentIntrinsically disordered proteins are potential drug targetsStrategically targeting MYC in cancerGenetics and biology of pancreatic ductal adenocarcinomaCancer: we should not forget the pastThe role of MIZ-1 in MYC-dependent tumorigenesisThe "virgin birth", polyploidy, and the origin of cancerSmall-molecule inhibitors of the Myc oncoproteinMYC activation is a hallmark of cancer initiation and maintenancePreclinical mouse cancer models: a maze of opportunities and challenges.MYC is a metastasis gene for non-small-cell lung cancerCrystal Structure of the Minimalist Max-E47 Protein ChimeraOmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumorsDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideThe role of tumor microenvironment in therapeutic resistanceTherapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseasesA SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesisBET domain co-regulators in obesity, inflammation and cancerIdentification of cytotoxic drugs that selectively target tumor cells with MYC overexpressionThe impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-mycRegistered report: BET bromodomain inhibition as a therapeutic strategy to target c-MycInhibitor of MYC identified in a Kröhnke pyridine libraryMethyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosisc-Rel deficiency increases caspase-4 expression and leads to ER stress and necrosis in EBV-transformed cellsInhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSilencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaMYC on the path to cancerInferring gene dependency network specific to phenotypic alteration based on gene expression data and clinical information of breast cancerDirect inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.Obesity and cancer pathogenesis.Max-E47, a designed minimalist protein that targets the E-box DNA site in vivo and in vitro.A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells.
P2860
Q24296476-0102EBFF-F2F8-478D-82CF-B1BE6850BD91Q24300934-054264F7-B38C-4B02-A647-38810CC942DAQ24302544-2248293F-2C72-4A3B-AAD5-529782BE6AD7Q24317029-DBE8474A-3201-442A-831A-42948B28A476Q24611142-02E0890A-3CD1-47AE-B6EF-51E5B2D8B95CQ24613516-F89F921B-D42D-460F-967C-04379F1B4E5BQ24621218-F92A4F49-4789-44DD-875F-29AEF7A4E71AQ24622802-896520C3-C8EB-41DF-9A66-FFE76843F401Q24633854-B45C3B40-88DB-4131-9E66-69A5D0CCBE97Q26747745-E76504D7-A30B-4AEB-8E55-5BDB8255750EQ26765438-B8EA79C3-7473-4407-B90E-1E1AE147C786Q26828818-86BA4581-8792-4159-AE1C-50677629AD22Q27010254-A136CC62-DCB8-41E0-9945-83C295DFD7EAQ27024916-A9D040F8-C27E-44F3-AF28-14AACDE14BAAQ27025648-97AF0F29-3C37-46BB-B6B3-3045B20322D7Q27026026-3DC4B4AB-51C9-4908-92C1-5998A6559298Q27322080-8556B9D0-D5F2-4C32-9728-7250D16EABFAQ27347283-6DFBD5EE-D6C9-42A4-9FBA-44E55B6417B1Q27677836-9A2CE843-3452-4C92-B947-DDF90E0D6143Q27728475-0729DFF4-C2C3-413E-B1B4-0E7D8FEC910AQ28067306-C8622E94-B056-465C-84B8-15FFFA5FC32BQ28069049-5BAF48C0-B5C4-42F6-8BFC-E02E503094DEQ28071309-17B20F7A-A651-4A06-8D73-77B9F1BB847EQ28255073-C183B3DC-F188-4F03-AAB8-D2042BD3A552Q28269301-A41CEAA2-80A7-452D-A29D-F7D765D781AEQ28478132-0912CA47-72B3-416F-95BB-6E6538FE0EE4Q28481319-1BA2A344-92EA-471E-9A76-4D376863F968Q28647939-0E0BD5B2-429A-4779-8BB3-361C2BDE3423Q28656132-B7798903-9915-48C1-9772-EC1640EDE0ECQ28658683-D25291E5-1DB0-4E98-92A3-087D41296168Q28744344-79351407-14EE-431E-8176-ED7AE2E5B52DQ28817295-BAD90354-A21F-452C-82D3-3F99D31438E6Q28817964-AD624A9B-93F8-4835-915E-844A4AA6DA96Q29617201-7D07E8C3-250D-4BDE-80EE-BBD8DAA95F6FQ29619979-A17EDDCE-0D5E-427D-995B-7CEAE1695C22Q30000682-18BAD1D4-B6D2-4D01-B278-D3331E2609BAQ30278518-4DEE41B0-E3C1-4C86-A6CF-4D3406BD543AQ30361298-51A4347B-9DFD-4203-A2C5-8D7A4A8622D0Q30377167-0DE28509-D691-4279-B7CF-57C9118A6AC1Q30413354-E77FA3EF-27A7-4A0C-807F-BD833C7B11B8
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Modelling Myc inhibition as a cancer therapy.
@ast
Modelling Myc inhibition as a cancer therapy.
@en
Modelling Myc inhibition as a cancer therapy.
@nl
type
label
Modelling Myc inhibition as a cancer therapy.
@ast
Modelling Myc inhibition as a cancer therapy.
@en
Modelling Myc inhibition as a cancer therapy.
@nl
prefLabel
Modelling Myc inhibition as a cancer therapy.
@ast
Modelling Myc inhibition as a cancer therapy.
@en
Modelling Myc inhibition as a cancer therapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Modelling Myc inhibition as a cancer therapy.
@en
P2093
Andrew J Finch
Anthony N Karnezis
Carla P Martins
Gerard I Evan
Lamorna Brown Swigart
Nicole M Sodir
Sergio Nasi
P2860
P2888
P304
P356
10.1038/NATURE07260
P407
P577
2008-08-17T00:00:00Z
P6179
1002917648